Search Clinical Trials in the European Union

Duration
Visits
Efficacy phase (II)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
1121-1140 of 1,738 trials

Diabetic Macular Edema: Dexamethasone Implant Study

We are investigating a new treatment using a dexamethasone implant for patients with diabetic macular edema. The goal is to see if it improves vision and how well patients tolerate the treatment.

Diabetic Macular Oedema>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesEndocrinologyOphthalmology

Breast Cancer: Patritumab Deruxtecan with Pembrolizumab

We are studying a new treatment combination for high-risk early-stage breast cancer patients to see if it improves tumor response compared to standard chemotherapy. This trial will help us understand the safety and effectiveness of this new approach.

Triple Negative Breast Cancer1-2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesOncology

PBP1510 for Advanced Pancreatic Cancer

We are studying a new treatment called PBP1510 in patients with advanced pancreatic cancer that has not responded to previous chemotherapy. The trial will evaluate its safety and effectiveness, both alone and with another drug, gemcitabine.

Advanced Pancreatic CancerSafety phase (I)Efficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesPartially RemoteOncology

Short-Term Insomnia: Neurexan® Treatment

We are exploring whether Neurexan® can improve sleep quality and daytime performance in people with short-term insomnia. This study compares its effects to a placebo to understand its potential benefits.

Short-Term Insomnia>2 yearsEfficacy phase (II)6-10 visitsStandard MedicinesPartially RemoteNeurologyPsychiatry

Kidney Transplant: Regulatory T Cell Therapy

We are studying the safety of using regulatory T cells in kidney transplant recipients to see if it helps the body accept the new kidney better. This may allow for less reliance on standard immunosuppressive medications.

Kidney TransplantationSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteInternal MedicineNephrology

Ileal Crohn’s Disease: AZD7798 Study

We are testing the safety and effectiveness of AZD7798 in adults with ileal Crohn’s disease who have an ileostomy. This study aims to see how well the treatment helps with healing and managing symptoms.

Crohn's Disease1-2 yearsEfficacy phase (II)16-20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteGastroenterologyInternal Medicine

Nivolumab and Entinostat for High-Risk Cancers in Kids

We are exploring a new treatment combining Nivolumab and Entinostat for children and adolescents with hard-to-treat cancers. The study aims to see if this combination can help those with specific tumor characteristics.

Relapsed or Refractory High-Risk Malignant Disease>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesOncologyPediatrics

Metastatic Colorectal Cancer: Valproic Acid and Standard Treatment

We are studying a new combination of Valproic acid with standard therapies for patients with metastatic colorectal cancer who have already been treated. The goal is to see if this combination improves survival and quality of life compared to standard treatment alone.

Metastatic Colorectal Cancer3-6 monthsEfficacy phase (II)No PlaceboStandard MedicinesGastroenterologyOncology

Fibrotic Lung Disease: Wharton's Jelly Stem Cells

We are studying the safety and effects of a stem cell treatment for people with fibrotic interstitial lung diseases. This research aims to see if it can improve lung function and quality of life.

Interstitial Lung Disease1-2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsInvestigational MedicinesInternal MedicinePulmonology

Epcoritamab for Relapsed Large B-Cell Lymphoma

We are studying the effectiveness of Epcoritamab as a second-line treatment for patients with relapsed or refractory large B-cell lymphoma. This trial aims to see how well it works and how safe it is compared to other treatments.

Diffuse Large B-cell Lymphoma1-2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesHematologyOncology

Ewing's Sarcoma: Naxitamab Treatment Study

We are evaluating the safety and effectiveness of naxitamab added to standard chemotherapy for patients with refractory Ewing's sarcoma. This study aims to see if this combination can improve treatment outcomes.

Ewing's Sarcoma>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesOncologyPediatrics

Low Ovarian Reserve: Factor-Rich Plasma Treatment

We are studying whether Factor-Rich Plasma injections can improve ovarian function and increase pregnancy rates in women with low ovarian reserve. This trial will also monitor any potential complications from the treatment.

Low Ovarian Reserve1-2 yearsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesGynecology and ObstetricsInternal Medicine

Cognitive Dysfunction in Schizophrenia: Clemastine and Exercise Study

We are investigating whether combining Clemastine with aerobic exercise can improve cognitive function in people with schizophrenia. The study aims to see if this approach enhances memory and overall functioning.

Schizophrenia>2 yearsEfficacy phase (II)≤5 visitsStandard MedicinesPsychiatry

AMG 193 for Advanced Non-Small Cell Lung Cancer

We are studying a new treatment, AMG 193, for patients with advanced non-small cell lung cancer that has a specific genetic deletion. The trial aims to evaluate its safety and effectiveness compared to existing options.

Non-Small Cell Lung Cancer>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementOncology

Advanced NSCLC: MCLA-129 Treatment Study

We are evaluating a new bispecific antibody, MCLA-129, for patients with advanced non-small cell lung cancer. The study aims to assess its effectiveness and safety compared to standard treatments.

Solid TumorsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesOncology

Advanced Lung Cancer: ABBV-400 and Budigalimab Study

We are testing a new treatment combining ABBV-400 and Budigalimab for adults with advanced non-squamous lung cancer who haven't had prior treatment. The goal is to see how safe it is and how well it works.

Advanced Non-Small Cell Lung CancerSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Breast Cancer: Shorter Hormone Therapy Duration

We are studying whether limiting hormone therapy to 2 years is effective for women with hormone-sensitive breast cancer at very low risk of recurrence. This trial aims to assess the safety and quality of life during and after treatment.

Localized Luminal A Breast Cancer in Post-Menopausal Women>2 yearsEfficacy phase (II)16-20 visitsNo PlaceboStandard MedicinesPartially RemoteEndocrinologyOncology

Giant Cell Arteritis and Rheumatoid Arthritis: PET/CT Imaging Study

We are testing a new imaging method to see inflamed arteries in giant cell arteritis and inflamed joints in rheumatoid arthritis. This study aims to improve how we visualize and understand these conditions.

Giant Cell ArteritisRheumatoid Arthritis>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementCardiologyRheumatology

Giant Cell Arteritis: Imaging Study with [18F]fluor-PEG-folate

We are investigating how well a special imaging technique shows changes in arteries of patients with giant cell arteritis before and after treatment. This may help us understand the disease better and improve future care.

Giant Cell Arteritis6-12 monthsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesCost ReimbursementRheumatology

Severe Autoimmune Encephalitis: Bortezomib Study

We are investigating whether bortezomib is effective and safe for patients with severe autoimmune encephalitis. This trial focuses on individuals with specific autoantibodies related to their condition.

Autoimmune Encephalitis3-6 monthsEfficacy phase (II)6-10 visitsStandard MedicinesCost ReimbursementNeurologyRheumatology